Analyst Ratings for Pacific Biosciences of California (PACB) [Neutrals]
PACB Rating Summary
PACB Price Target Summary
- Highest: $13.00 (Piper Sandler)
- Lowest: $2.00 (Nephron)
- Average: $7.29
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$7.29 (+436.2%)
* Over Last 12-Mos
Rating Score: 4.5 / 10 Percentile Rank: 46%
Rating Score: 4.5 / 10 Percentile Rank: 46%
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
4/22/2024 | JPMorgan | Rachel Vatnsdal | Downgrade | Neutral (Overweight) |
N/A (N/A) |
1.46 (1.36) |
-6.85% | Details |
4/18/2024 | Goldman Sachs | Matthew Sykes | Downgrade | Neutral (Buy) |
2.50 (7.00) |
1.40 (1.36) |
-2.86% | Details |